SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:gup.ub.gu.se/286418"
 

Search: id:"swepub:oai:gup.ub.gu.se/286418" > Efficacy of alemtuz...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Van Wijmeersch, B. (author)

Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies

  • Article/chapterEnglish2020

Publisher, publication year, extent ...

  • 2019-11-01
  • SAGE Publications,2020

Numbers

  • LIBRIS-ID:oai:gup.ub.gu.se/286418
  • https://gup.ub.gu.se/publication/286418URI
  • https://doi.org/10.1177/1352458519881759DOI

Supplementary language notes

  • Language:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Background:Alemtuzumab is administered as two annual courses for relapsing-remitting multiple sclerosis (MS). Patients may relapse before completing the two-course regimen. Objective: The objective was to evaluate 6-year outcomes in patients who relapsed between alemtuzumab Courses 1 and 2 (early relapsers). Methods:Post hoc analysis of patients from the Comparison of Alemtuzumab and Rebif (R) Efficacy in Multiple Sclerosis (CARE-MS) studies who enrolled in the extension. Results:Early relapsers (CARE-MS I: 15%; CARE-MS II: 24%) had more relapses in 1-2 years pre-alemtuzumab and higher mean baseline Expanded Disability Status Scale score than patients without relapse. Their annualized relapse rate declined from Year 1 (CARE-MS I: 1.3; CARE-MS II: 1.2) to Year 2 following Course 2 (0.3; 0.5) and remained low thereafter. Over 6 years, 60% remained free of 6-month confirmed disability worsening; 24% (CARE-MS I) and 34% (CARE-MS II) achieved 6-month confirmed disability improvement. During Year 6, 69% (CARE-MS I) and 68% (CARE-MS II) were free of magnetic resonance imaging (MRI) disease activity. Median percent yearly brain volume loss (Year 1: -0.67% (CARE-MS I); -0.47% (CARE-MS II)) declined after Course 2 (Year 6: -0.24%; -0.13%). Conclusion: Early relapsers' outcomes improved after completing the second alemtuzumab course. These findings support administering the approved two-course regimen to maximize clinical benefit. ClinicalTrials.gov registration numbers:CARE-MS I, II, extension: NCT00530348, NCT00548405, NCT00930553.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Singer, B. A. (author)
  • Boster, A. (author)
  • Broadley, S. (author)
  • Fernandez, O. (author)
  • Freedman, M. S. (author)
  • Izquierdo, G. (author)
  • Lycke, Jan,1956Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi,Institute of Neuroscience and Physiology(Swepub:gu)xlycja (author)
  • Pozzilli, C. (author)
  • Sharrack, B. (author)
  • Steingo, B. (author)
  • Wiendl, H. (author)
  • Wray, S. (author)
  • Ziemssen, T. (author)
  • Chung, L. (author)
  • Margolin, D. H. (author)
  • Thangavelu, K. (author)
  • Vermersch, P. (author)
  • Göteborgs universitetInstitutionen för neurovetenskap och fysiologi (creator_code:org_t)

Related titles

  • In:Multiple Sclerosis Journal: SAGE Publications26:13, s. 1719-17281352-45851477-0970

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view